trending Market Intelligence /marketintelligence/en/news-insights/trending/tbvdrknalst95npzduhslq2 content esgSubNav
In This List

Mallinckrodt secures additional $26M in US funding to develop burn therapy

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Mallinckrodt secures additional $26M in US funding to develop burn therapy

Mallinckrodt PLC said it will receive an additional $26 million from the U.S. government to study its burn therapy StrataGraft in children.

The additional award from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, pushes total government funding for the therapy to $86 million. The U.K.'s Mallinckrodt can secure up to an additional $160 million for StrataGraft, which is being developed by its subsidiary Stratatech Corp. as a medical countermeasure for large-scale burn incidents.

StrataGraft is a human skin substitute that is yet to be approved by the U.S. Food and Drug Administration. The regulator has designated StrataGraft as a regenerative medicine advanced therapy, which will allow for an accelerated review process.

StrataGraft, which is designed to work like natural skin, is being studied in a phase 3 trial for adults.

BARDA is a division of the U.S. Department of Health and Human Services tasked with the procuring and developing countermeasures against bioterrorism, including chemical, nuclear and radiological threats, as well as pandemic influenza and emerging diseases.